Lipfendra: What the New Cholesterol Pill Does and Does Not Prove
Lipfendra is an oral PCSK9 inhibitor that lowers LDL cholesterol. Understand the approval, how the pill differs from injections, and the limits of stroke evidence.
Prepared with AI assistance and checked against the linked sources. The update date records an editorial revision; it does not certify physician review.
What you need to know about the first cholesterol pill in the PCSK9 class.
- On July 15, 2026, the FDA approved Lipfendra (enlicitide) — the first FDA-approved oral PCSK9 inhibitor. Every prior PCSK9 drug had to be injected.
- In the pivotal CORALreef Lipids trial it lowered LDL ("bad") cholesterol by about 57% — an adjusted difference of roughly 56 percentage points versus placebo — from a single 20 mg pill.1
- Head-to-head, it outperformed the other oral non-statin options — ezetimibe and bempedoic acid — cutting LDL by about 65% versus 28% and 6%.2
- Why a neurologist cares: lowering LDL is one of the most proven ways to prevent ischemic stroke. An injectable PCSK9 inhibitor cut ischemic strokes by about a quarter — without a statistically significant difference in hemorrhagic stroke in that trial.3
- The catch: Lipfendra is proven to lower cholesterol, but its heart-attack-and-stroke outcomes trial is still running (CORALreef Outcomes, 14,500+ patients).
What approval establishes
The FDA approved Lipfendra to lower LDL cholesterol in adults with hypercholesterolemia. That is different from an approval based on demonstrated reduction of stroke events. Read the FDA announcement.
Results from injectable PCSK9 inhibitors cannot simply be assigned to a different drug. The outcome-trial discussion below explains why the distinction matters.
The FDA approval letter for Lipfendra (enlicitide) is signed July 15, 2026. Approval establishes an oral option for LDL lowering; it does not establish that enlicitide itself prevents strokes. FDA approval letter.
As a vascular neurologist, I read this news through one lens above all others: the brain. LDL cholesterol is not just a heart problem. It is one of the most consistent, most modifiable drivers of the ischemic strokes I treat. A more convenient way to drive it down is, potentially, a more convenient way to protect the brain.
Why cholesterol is a brain problem, not just a heart problem
LDL cholesterol — the "bad" cholesterol — drives the buildup of plaque inside artery walls. In the heart, that plaque causes heart attacks. In the arteries feeding the brain, the same process narrows vessels, throws clots downstream, and causes strokes. It is the same disease in two different addresses.
LDL lowering has reduced vascular events in trials of several treatments, but the evidence must be matched to the drug and population. FOURIER studied injectable evolocumab added to statins in people with established atherosclerosis; its stroke findings should not be presented as enlicitide results.3 A prior brain hemorrhage also calls for an individualized risk discussion rather than a blanket safety claim.
Statins remain the foundation of treatment. But many patients cannot get their LDL low enough on a statin alone, and some cannot tolerate statins at all. That gap — the "I'm on a statin and my number is still too high" patient — is exactly where PCSK9 inhibitors were built to help.
How Lipfendra works — and why it took so long to make a pill
PCSK9 is a protein that behaves like a wrecking crew for the liver's cholesterol-clearing machinery. Your liver pulls LDL out of the blood using structures called LDL receptors. PCSK9 tags those receptors for destruction. The more PCSK9 you have, the fewer receptors survive — and the more LDL stays circulating in your blood.
Block PCSK9, and the receptors get recycled instead of destroyed. The liver clears far more LDL, and blood cholesterol falls.
The existing PCSK9 inhibitors — alirocumab and evolocumab — are monoclonal antibodies: large proteins that the digestive system would destroy if swallowed, which is why they must be injected every two to four weeks. Merck's advance is chemical. Lipfendra is a macrocyclic peptide — a smaller, ring-shaped molecule engineered to survive the gut and be absorbed as a 20 mg pill taken once a day. The FDA label describes a once-daily oral formulation.
The evidence: the CORALreef trials
Approval rested on the Phase 3 CORALreef program — large, randomized, double-blind, placebo- and active-controlled trials.
In CORALreef Lipids, published in the New England Journal of Medicine, 2,909 adults with or at risk for cardiovascular disease were randomized to Lipfendra or placebo. At 24 weeks, LDL fell by 57.1% with the pill and rose 3.0% on placebo — an adjusted between-group difference of −55.8 percentage points — and the effect was sustained through a full year.1 The drug also significantly lowered non-HDL cholesterol, apolipoprotein B, and lipoprotein(a) — markers many of us consider even better gauges of the total burden of artery-clogging particles than LDL alone.
Then there is the question every clinician actually asks: is it better than the pills I already have? In the head-to-head CORALreef AddOn trial, published in the Journal of the American College of Cardiology, Lipfendra was compared directly against the other oral non-statin options in statin-treated patients. The LDL reductions were not close:2
- Lipfendra (enlicitide): −64.6%
- Bempedoic acid + ezetimibe: −36.5%
- Ezetimibe alone: −27.8%
- Bempedoic acid alone: −6.3%
An additional trial in patients with heterozygous familial hypercholesterolemia — an inherited condition that causes dangerously high LDL from birth — showed a similar reduction of roughly 59%.
How safe is it?
In the FDA label’s HeFH trial, diarrhea occurred in 7% on enlicitide versus 2% on placebo, and dizziness in 9% versus 4%. Similar discontinuation rates do not mean a medicine is harmless. Pregnancy, breastfeeding, other medicines and individual health conditions belong in the prescribing discussion. FDA prescribing information.
The one question the data has not answered yet
Here is where I put on the brakes. Lowering LDL is a means, not the end. The end that matters to patients is fewer strokes, fewer heart attacks, and longer lives. So far, Lipfendra is proven to move the number on the lab report. It has not yet been proven to reduce cardiovascular events.
The CORALreef Outcomes registry lists an active trial with estimated enrollment of 14,550 and no posted results in the record checked for this update. It measures cardiovascular events, including ischemic stroke. Enrollment and expected completion dates are not results, and benefit must not be assumed before the trial reports.
What this means for patients
Lipfendra is approved as an add-on to diet and exercise to lower LDL in adults with high cholesterol, including those with familial hypercholesterolemia. It is aimed at people who need more LDL lowering than a statin alone delivers, and at those who cannot tolerate statins.
- If your LDL is still high on a statin, this is a genuinely new oral option worth discussing with your physician — one that, in trials, outperformed the other pills in its category.
- If you have had a stroke or TIA, LDL management may be an important part of secondary prevention, depending on stroke type and cause. A pill that avoids injections may make it easier to actually stay on treatment. Our guide to the first steps after a stroke covers where cholesterol fits into recovery.
- Do not stop a statin on your own to "wait for the pill." Statins have decades of outcomes data behind them; Lipfendra's outcomes data is still being gathered.
Whether an oral medicine fits better depends on cost, coverage, routine and tolerability. Its administration requirements also matter: the label specifies morning dosing on an empty stomach and waiting at least 30 minutes before food. Ask the pharmacist to review the full instructions with your medication list. A tablet should not be assumed easier for every person, and it is not a direct interchangeable version of an injectable drug.
A decision sheet for the prescribing visit
| Question | Write down |
|---|---|
| What are we trying to improve? | My LDL result, agreed target and reason for treatment. |
| What evidence applies to me? | LDL-lowering evidence versus completed cardiovascular-outcome evidence. |
| How does this fit my routine? | Administration instructions, other medicines and affordability. |
| How will we assess the result? | When to repeat testing, side effects to report and follow-up contact. |
This original conversation aid does not select a medicine for you. This article is educational; medication changes require your treating clinician.
Frequently asked questions.
What is Lipfendra (enlicitide)?
Lipfendra is the brand name for enlicitide, the first once-daily oral PCSK9 inhibitor approved by the FDA (July 15, 2026). It lowers LDL ("bad") cholesterol and is taken as a 20 mg pill, unlike earlier PCSK9 inhibitors, which must be injected every two to four weeks.
How much does Lipfendra lower cholesterol?
In the Phase 3 CORALreef Lipids trial, LDL cholesterol fell about 57% at 24 weeks — with an adjusted difference of roughly 56 percentage points compared with placebo — and the effect was sustained for a year. In a head-to-head trial it lowered LDL by about 65%, outperforming ezetimibe (about 28%) and bempedoic acid (about 6%).
Does lowering LDL cholesterol prevent stroke?
Yes. Lowering LDL is one of the most well-established ways to reduce ischemic stroke risk. In the FOURIER trial, the injectable PCSK9 inhibitor evolocumab reduced ischemic strokes by about 25% without a statistically significant difference in hemorrhagic stroke in that trial. Whether Lipfendra specifically reduces strokes is still being tested in a large outcomes trial.
What are the side effects of Lipfendra?
Dizziness and diarrhea occurred more often than placebo in the HeFH trial. The detailed rates and FDA label are linked in the safety section. Trial averages do not predict an individual’s experience; discuss new symptoms with the prescribing team.
Is Lipfendra proven to prevent heart attacks and strokes?
Not yet. Lipfendra is proven to lower LDL cholesterol dramatically, but the cardiovascular outcomes trial (CORALreef Outcomes, more than 14,500 participants) is still underway to confirm whether it reduces heart attacks, strokes, and cardiovascular death.
Who is Lipfendra for?
It is approved as an add-on to diet and exercise for adults with high LDL cholesterol, including those with heterozygous familial hypercholesterolemia, who need further LDL lowering despite statin therapy or who cannot tolerate statins.
References.
- Navar AM, Mikhailova E, Catapano AL, et al. A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide (CORALreef Lipids). N Engl J Med. 2026. doi:10.1056/NEJMoa2511002 · PubMed
- Catapano AL, Mikhailova E, Navar AM, et al. Oral PCSK9 inhibitor enlicitide versus oral nonstatin therapies: a phase 3 randomized clinical trial (CORALreef AddOn). J Am Coll Cardiol. 2026. doi:10.1016/j.jacc.2026.03.036 · PubMed
- Giugliano RP, Pedersen TR, Saver JL, et al. Stroke prevention with the PCSK9 inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis (FOURIER). Stroke. 2020;51(5):1546-1554. doi:10.1161/STROKEAHA.119.027759 · PubMed
- Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease (FOURIER). N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664 · PubMed
- Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome (ODYSSEY OUTCOMES). N Engl J Med. 2018;379(22):2097-2107. doi:10.1056/NEJMoa1801174 · PubMed
Article written by